Alps Advisors Inc. lessened its position in Illumina (NASDAQ:ILMN) by 13.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,895 shares of the life sciences company’s stock after selling 305 shares during the period. Alps Advisors Inc.’s holdings in Illumina were worth $448,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Gravity Companies Inc. bought a new position in shares of Illumina in the fourth quarter worth approximately $106,000. SeaCrest Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter worth approximately $154,000. Captrust Financial Advisors bought a new position in shares of Illumina in the fourth quarter worth approximately $165,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Illumina by 113.9% in the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after buying an additional 410 shares in the last quarter. Finally, Riverbridge Partners LLC bought a new position in shares of Illumina in the fourth quarter worth approximately $202,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

In other Illumina news, CEO Francis A. Desouza sold 2,100 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $268.63, for a total transaction of $564,123.00. Following the completion of the sale, the chief executive officer now directly owns 87,371 shares of the company’s stock, valued at $23,470,471.73. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Oene Mark Van sold 1,408 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $228.85, for a total transaction of $322,220.80. Following the sale, the senior vice president now directly owns 15,760 shares of the company’s stock, valued at $3,606,676. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,022 shares of company stock valued at $4,340,645. 0.54% of the stock is owned by corporate insiders.

Several research analysts have recently issued reports on ILMN shares. Morgan Stanley upped their target price on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 31st. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 19th. Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and upped their target price for the stock from $260.00 to $275.00 in a research note on Monday, February 5th. Cowen upped their target price on shares of Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a research note on Monday, January 22nd. Finally, First Analysis raised shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price objective for the company in a report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $251.14.

Shares of ILMN stock opened at $268.84 on Thursday. Illumina has a 12 month low of $264.12 and a 12 month high of $267.94. The company has a market cap of $39.61 billion, a price-to-earnings ratio of 67.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.86. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The business had revenue of $782.00 million during the quarter, compared to analysts’ expectations of $744.30 million. During the same period in the prior year, the company earned $0.64 earnings per share. The firm’s revenue was up 30.8% on a year-over-year basis. research analysts predict that Illumina will post 4.87 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.